Early Onset Favipiravir Saves Lives

Ercan KARATAS (✉ canertaskara@hotmail.com)

Turkiye Cumhuriyeti Saglik Bakanligi   https://orcid.org/0000-0002-3133-4199

Lacin Aksoy

Marmara Universitesi Tip Fakultesi, Family Practicies

Pinar Elbir Kilic

İstanbul Tuzla State Hospital

Arzu Dogru

Tuzla State Hospital: Tuzla Devlet Hastanesi

Ersin Ozaslan

Acibadem Hospitals Group: Acibadem Saglik Grubu

Research

Abstract

Background

Favipiravir, an antiviral recommended for use in patients with tachypnea (respiratory rate 30 / min) in COVID-19 pneumonia, with SpO2 level below 90% in room air and with bilateral diffuse pneumonia on chest X-ray or tomography, or patients with treatment-resistant fever, is a new type of RNA-dependent RNA polymerase (RdRp) inhibitor. After the administration of Favipiravir, it contributed significantly to reducing mortality in patients with severe COVID-19 positive disease. We performed this study to determine the start time in Favipiravir's covid pneumonia.

Material and Method:

We evaluated the effect of a total of 5 days of oral treatment as a 2 × 1600 mg loading dose and a 2 × 600 mg maintenance dose of Favipiravir added to the standard COVID-19 treatment received by patients with laboratory-radiology-clinical findings who have advanced or severe COVID 19 pneumonia.

Results

180 patients hospitalized at Tuzla State Hospital and given Favipiravir treatment between 20/3/2020 and 30/5/2020 were examined. As of hospitalization, 17 of 101 patients (17%) who were given Favipiravir treatment in ≤ 3 days died, 30 of 79 patients (38%) who were given Favipiravir treatment for in > 3 days died (p:0.002). 33 of 47 patients (70%) who died were > 65 years old. Only 5 of the 47 (11%) patients who died had no comorbid disease. 35 had two or more comorbid diseases.

Conclusion

Patients with radiological findings indicating that COVID-19 will be severe and laboratory findings at the time of the first 3 days should be initiated with an effective dose of Favipiravir treatment without waiting for the clinical worsening.

1 Background

SARS-CoV-2 is an enveloped, positive-polarity, and single-stranded RNA virus that belongs to the beta-coronavirus group. SARS-CoV-2 is a zoonotic pathogen and can cause symptoms ranging from mild clinical course to severe lower respiratory tract infection (ARDS) when it infects humans [1]. SARS-CoV-2 has a genetic similarity of 79% to SARS-CoV, 50% to MERS-CoV, and ~ 96% to coronaviruses found in bats. The main feature of SARS-CoV-2, which appears to have been formed as a result of a new mutation, is that it easily binds to the ACE2 receptor, especially lung type 2 alveoli cells in humans, and uses the ACE2 receptor as the entry gate to the cells [2]. Replication of the virus, which enters the cell by binding to

ACE2, begins, and the inflammatory reaction chain is triggered [3]. Depending on the age of the host and the immune system, the severity of the inflammatory reaction occurs [4]. It mainly affects the natural immune system and leads to the release of cytokines [5]. They are viruses with positive polarity. They do not contain RdRp enzymes but the genetic structure to code. They produce this enzyme in the host cells they enter. In the presence of an effective RNA-dependent RNA polymerase inhibitor, it is thought that this drug may be effective against the replication of the virus and possible mutations that the virus may pass through [6]. SARS-CoV-2 is mainly spread through droplets and direct contact. The contagious rate is high [7]. The average incubation period of COVID-19 infection is 5.5 days. However, it was reported that it could extend up to 14 days [8]. The most common symptoms are fever, fatigue, muscle pain, sore throat and dry cough, dyspnea, less commonly nausea, vomiting, and diarrhea [9]. In 80% of the cases, the symptoms are mild-moderate [10] In mild cases, there may be complaints similar to upper respiratory tract infection, mild fever, and muscle pain that do not affect daily life, and there may not be any symptoms during the contagious period. Another characteristic of patients who develop severe COVID-19 infection is a high viral load and prolonged virus excretion [11]. The main cause of hospital admissions is pneumonia. Causes of death are respiratory failure, circulatory failure due to myocardial damage, and respiratory and circulatory failure [12]. Although various protocols have been tried in the treatment of COVID-19, there is still no standard treatment option established by traditional evidence-based methods. 200 mg hydroxychloroquine sulfate twice a day for 5 days and oseltamivir in cases in which influenza cannot be excluded, azithromycin, and/or hydroxychloroquine sulfate for 5 days in patients diagnosed with uncomplicated probable/definite COVID-19, age (> 50), risk factors or low prognosis indicators and oseltamivir in cases in which influenza cannot be excluded, azithromycin, hydroxychloroquine sulfate and/or Favipiravir for 5 days in cases with severe pneumonia and oseltamivir in cases where influenza cannot be excluded, and Favipiravir or lopinavir 200 mg/ritonavir 50 mg tablets for 10–14 days in addition to hydroxychloroquine in patients whose clinical condition became severe or whose pneumonia symptoms progressed while receiving hydroxychloroquine treatment were recommended for treatment. As a support treatment, antibiotic administration is recommended in ARDS cases, including 1–2 mg/kg/day, methylprednisolone for 5–7 days with a "poor level of evidence," and in severe pneumonia by including atypical pneumonia. Anti-cytokine/anti-inflammatory treatments such as Tocilizumab and Anakinra can be tried in patients with macrophage activation syndrome (MAS) characterized by a cytokine storm. Coronavirus can lead to thromboembolic complications as a result of vascular microthrombotic disease in patients who develop stasis or sepsis directly associated with endothelial damage, inactivity, or hospitalization. Therefore, low molecular weight heparin (enoxaparin 40 mg/day) prophylaxis should be administered to all COVID-19 patients [13].

2 Material And Methods

2.1 Patients

This study was carried out in Tuzla State Hospital with the approval of the Marmara University Faculty of Medicine Ethics Committee after obtaining permission from the Scientific Research Unit of the Ministry of

Health and with the permission of Istanbul Provincial Health Directorate(Marmara University Dean Of Faculty of Medicine Faculty of Medicine Research Ethics Commitee numbered: E.70737436-050.01.04-2000202899, 29.09.2020). Our study was conducted in accordance with the Decleration of Helsinki Principles. Patients with severe COVID-19 pneumonia who were admitted to Tuzla State Hospital between 20/3/2020 and 30/5/2020 and treated with Favipiravir at any stage of their treatment were examined retrospectively. The study included patients aged over 18, non-pregnant (for women), with or without comorbid, and those who have severe pneumonia (respiratory rate > 30/min) and/or severe respiratory distress (dyspnea or use of extra respiratory muscles) and/or fingertip oxygen saturation < 90% (PaO2/FiO2 < 300 in patients receiving oxygen) and were treated with Favipiravir at any stage of their treatment and have bilateral multi-lobar ground glass densities in computed tomography (CT).

3 Statistical Analysis

The research data were collected retrospectively through the Tuzla State Hospital registration system. Descriptive statistics, categorical variables, and mean ± SD or median and interquartile range for continuous variables. Comparisons were determined by t-test. The SPSS 22.0 statistics method was used.

4 Results

We examined 180 patients hospitalized in Istanbul Tuzla State Hospital and treated with Favipiravir between 20/3/2020 and 30/5/2020. The mean age of the patients is 59 ± 17.4. The number of patients aged ≤ 65 years is 108, and ≤ 65 years old mortality rate is 12%. 15 of 108 patients died. The average age of the patients who died was 71.0 ± 14.7, and the average age of the recovered patients was 54.7 ± 16.3 (p < 0.001). The number of patients aged > 65 years is 72 patients, and the mortality rate is 45%. 32 of 72 patients died. This means that the mortality rate increases as age increases. While the mortality rate was 64% in males and 36% in females (17 of the 47 patients who died were female and 30 were male)(Fig. 1). It was found that those with one or more comorbidities had higher mortality rates. We observed that as the number of comorbidities increased, the mortality rate increased. The comorbidities of patients were listed as hypertension (79 patients have a diagnosis of hypertension, 29 patients use ACEIs, and 36 patients use ARB), hyperlipidemia (57 patients diagnosed with hyperlipidemia), diabetes mellitus (52 patients with diabetes mellitus diagnosis), and CAH (33 patients with a diagnosis of CAH). Of the 47 patients who died, 42 had at least one comorbid disease (89%). 63% of 180 patients had at least one comorbid disease (Fig. 2). When the symptoms at admission are evaluated, cough (52%, 94 patients), dyspnea (47%, 86 patients), and fever (45%, 82 patients) are the first three clinical findings (Fig. 3).

When the blood types of the ex-patients were examined, blood type A was the majority (Fig. 4). When we examined the blood types, the A blood type mortality was found to be the highest. While the A blood type was 55% in all patients, the A blood group was 68% in the ex-patients. The rate of A blood group was higher than the non A-blood groups, among ex patients. (p:0.03). Anemia, leukocytosis, neutrophilia,

lymphopenia, and thrombocytosis were found in the hemogram of the patients at the time of the first application, who later died. We found that ex-patients had significantly higher levels of CRP, D-dimer, LDH, and Ferritin. When we evaluated the Favipiravir initiation time after hospitalization, we found that the mortality rate was significantly lower in those who received Favipiravir treatment within the first 72 hours of hospitalization (p:0.002) (Fig. 5). Regarding patient characteristics, there was no difference between the characteristics of patients who were started favipiravir in the first 3 days and after 3 days (p > 0.05) (Table 1).

Table 1
Comparison of ≤ 3 day and > 3 day Favipiravir initiation by patient characteristics

Patient Characterisitics	≤ 3 day Favipiravir initiation (n:101)	> 3 day Favipiravir initiation (n:79)	P value
Mean age	58.0 ± 16.1	60.4 ± 18.9	0.34
Age			0.19
≤ 65 years	58	53	
> 65 years	43	26	
Sex			0.09
Female	36	37	
Male	65	42	
Number of comorbidity			0.12
0	34	29	
1	11	11	
2	17	9	
≥3	37	29	
Blood group type			0.36
A	41	19	
Non-A	24	22	

5 Discussion

Based on the experience of other viral infections, the opinion prevails that early antiviral therapy will be more useful in the treatment of COVID-19. The most important benefit of early antiviral therapy is that it reduces the rate of viral replication. The most experience of the benefits of early antiviral therapy has

been observed during Influenza treatment [14, 15]. It has been reported that early antiviral therapy is necessary and benefical in many clinical trials on Covid-19. In some of these trials;

Magleby et al., A retrospective cohort study from New York in 678 hospitalized patients with COVID-19 showed high viral load was independently associated with mortality (adjusted odds ratio [aOR] 6.05 and p < 0.001) and intubation (aOR 2.73 and p < 0.001) than patients with medium and low viral load [16]. Wue et al., Only comorbidity and time from illness to antiviral treatment are statistically significantly associated with the severity of disease in the multivariate analysis. It has also shown that the time for antiviral therapy initiation is significantly shorter in mild illness as compared to severe illness[17]. Early antiviral therapy prevents increased viral load in the lower respiratory tract. Save time to inactivate the virs in the upper respiratory tract. Weiss et al., Viral load in the upper respiratory tract peaks early in mild patients (4 days) as compared to in moderate-severe patients(8 days). Similarly, viral load in lower respiratory tract (LRT) peaks early in mild patients (6 days) than in moderate-severe patients (11days). It shows how important early diagnosis and time to start to treatment[18]. Doi et al., Describe successful treatment of patients with early COVID-19 with favipiravir, an oral polymerase inhibitor, to rapidly and substantially clear SARS-CoV-2 from nasal secretions irrespective if it was started relatively early or later within the first week of infection[19]. Goyal et al., It has been reported that if a patient receives antiviral therapy in the early phase of infection, there are high chances that the duration of shedding and intensity of the effector immune response may decrease; however, there may be a limited impact on viral area under the curve (AUC) possibly owing to higher levels of early SARS-CoV-2 replication[20]. Early antiviral therapy can effectively shorten the virus clearance time and prevent the rapid progression of COVID-19. Therefore, COVID-19 patients should receive combination treatments with antiviral treatment at an early stage. Saber Ayed et al., The antiviral drugs administered shortly after the onset of symptoms can shorten the course of clinical illness and it can reduce the infectiousness to others by reducing viral shedding[21]. Wu J et al., Found that older adults and patients with underlying diseases are more likely to experience severe COVID-19 progression. It is recommended to start antiviral treatment in time to slow the progression of the disease and improve the prognosis[22]. SARS, MERS, and COVID-19 are viruses with similar genetic structures[23]. The benefit of early antiviral treatment has also been experienced in SARS and MERS infections, which have a similar genetic structure[24]. Similarly, since it is not known precisely in which patients will have a more severe course of viral infection, antiviral treatment should be initiated without delay, especially in the elderly, patients with multiple chronic diseases, and COVID-19 patients who meet the clinical and laboratory criteria for the severe disease at the time of onset[25]. Ting Yu et al. divided 129 confirmed mild to moderate COVID-19 patients who were treated with antiviral drugs at the time of their hospitalization at Wuhan Union Hospital, China, into the early antiviral treatment group and the late antiviral therapy group they included. Demographic data, laboratory tests, virus recovery time, and chest CT scans were collected, calculated, and compared between the two groups. The resulting data showed that the median time from the onset of the disease to the onset of antiviral treatment in all patients was 6 days. The group receiving early antiviral treatment showed 7 days shorter virus recovery time compared to the group receiving late antiviral treatment. After the virus was cleared, the group receiving early antiviral treatment showed milder disease than the group receiving late antiviral treatment.

Early antiviral treatment can effectively shorten the virus recovery time and prevent the rapid progression of COVID-19. Therefore, COVID-19 patients should receive treatments combined with antiviral treatment at an early stage[26].

In our study; similar to the above studies, we found that early antiviral therapy benefit and reduces mortality.

6 Conclusion

The primary defense mechanism against viral infections is the response formed by the humoral immune system. However, in some infectious diseases, such as COVID-19, the immune system may not be able to neutralize the virus. In these cases, it is necessary to use treatments that will reduce the rate of replication of the virus. Early antiviral drugs will reduce the rate of viral replication and save time for the humoral defense mechanism to neutralize the virus. In our study, we found that the initiation of Favipiravir, an RdRp inhibitor antiviral, within the first 72 hours after the onset of disease symptoms significantly reduced mortality. Nevertheless, the research has limitations, such as the fact that the study was conducted with the participation of a small group of patients.

Abbreviations

ACE2: Angiotensin-Converting Enzyme 2; ARB: Angiotensin Receptor *Blockers* ARDS:Acute Respiratory Distress Syndrome; CoV: Coronavirus; COVID19: Coronavirus disease 2019; MERS-CoV: Middle East Respiratory Syndrome Coronavirus; SARS-CoV: Severe Acute Respiratory Syndrome Coronavirus; RdRp: RNA-dependent RNA polymerase; MAS: Macrophage Activation Syndrome; CT: Computerized tomography

Declarations

Ethics approval and consent to participate

This study was carried out in Tuzla State Hospital with the approval of the Marmara University Faculty of Medicine Ethics Committee after obtaining permission from the Scientific Research Unit of the Ministry of Health and with the permission of Istanbul Provincial Health Directorate(Marmara University Dean Of Faculty of Medicine Faculty of Medicine Research Ethics Commitee numbered: E.70737436-050.01.04-2000202899, 29.09.2020).

Consent for publication

Not applicable

Availability of data and materials

The data and materials used during the current review are all available in this review.

Competing interests

Funding

Authors' contributions

Acknowledgements

Authors' information

Ercan Karatas [1], internal medicine doctor at İstanbul Tuzla State Hospital. Lacin Aksoy [2], family practician at Marmara University Medical Faculty. Pinar Elbir Kilic [3], clinical microbiology and infectious diseases doctor at İstanbul Tuzla State Hospital. Arzu Dogru [4], clinical microbiology and infectious diseases doctor at İstanbul Tuzla State Hospital.Ersin Ozaslan [5], medical oncolog at Acibadem Kayseri Hospital.

Authors' details

[1]Department of İnternal Medicine, Tuzla State Hospital, Istanbul 34959, Turkey. [2]Department of Family Practician, Marmara University Medical Faculty, Istanbul 34890, Turkey. [3]Department of Clinical microbiology and infectious diseases, Tuzla State Hospital, Istanbul 34959. [4]Department of Clinical microbiology and infectious diseases, Tuzla State Hospital, Istanbul 34959. [5]Department of Medical Oncology, Acibadem Hospitals Group, Kayseri, 38000.

References

1. Corman VM, Muth D, Niemeyer D, Drosten C. Hosts and Sources of Endemic Human Coronaviruses. *Adv Virus Res*. 2018;100:163-188.
2. Andersen KG, Rambaut A, Lipkin WI, Holmes EC, Garry RF. The proximal origin of SARS-CoV-2. *Nat Med*. 2020;26(4):450-452.
3. Tang T, Bidon M, Jaimes JA, Whittaker GR, Daniel S. Coronavirus membrane fusion mechanism offers a potential target for antiviral development. *Antiviral Res*. 2020;178:104792.

4. García LF. Immune Response, Inflammation, and the Clinical Spectrum of COVID-19. *Front Immunol*. 2020;11:1441. Published 2020 Jun 16.

5. Yazdanpanah F, Hamblin MR, Rezaei N. The immune system and COVID-19: Friend or foe?. *Life Sci*. 2020;256:117900.

6. Zhu W, Chen CZ, Gorshkov K, Xu M, Lo DC, Zheng W. RNA-Dependent RNA Polymerase as a Target for COVID-19 Drug Discovery. *SLAS Discov*. 2020;25(10):1141-1151.

7. Jayaweera M, Perera H, Gunawardana B, Manatunge J. Transmission of COVID-19 virus by droplets and aerosols: A critical review on the unresolved dichotomy. *Environ Res*. 2020;188:109819.

8. Lauer SA, Grantz KH, Bi Q, et al. The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application. *Ann Intern Med*. 2020;172(9):577-582.

9. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al , China Medical Treatment Expert Group for Covid-19 (2020). Clinical Characteristics of Coronavirus Disease 2019 in China. The New England journal of medicine, 382(18), 1708–1720.

10. Lima C. (2020). Information about the new coronavirus disease (COVID-19). Radiologia brasileira, 53(2), V–VI.

11. Liu, Y., Yan, L. M., Wan, L., Xiang, T. X., Le, A., Liu, J. M., Peiris, M., Poon, L., & Zhang, W. (2020). Viral dynamics in mild and severe cases of COVID-19. The Lancet. Infectious diseases, 20(6), 656–657.

12. Ruan, Q., Yang, K., Wang, W., Jiang, L., & Song, J. (2020). Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive care medicine, 46(5), 846–848.

13. Aktoz M, Altay H, Aslanger E, et al. (2020) Turkish Cardiology Association Consensus Report: COVID-19 Pandemic and Cardiovascular Diseases. 2020;48(Suppl 1):1-87.

14. Wang, Y., Wang, Y., Chen, Y., & Qin, Q. (2020). Unique epidemiological and clinical features of the emerging 2019 novel coronavirus pneumonia (COVID-19) implicate special control measures. Journal of medical virology, 92(6), 568–576.

15. Hsu, J., Santesso, N., Mustafa, R., Brozek, J., Chen, Y. L., Hopkins, J. P., et al. (2012). Antivirals for treatment of influenza: a systematic review and meta-analysis of observational studies. Annals of internal medicine, 156(7), 512–524.

16. Magleby R, Westblade LF, Trzebucki A, et al. Impact of SARS-CoV-2 Viral Load on Risk of Intubation and Mortality Among Hospitalized Patients with Coronavirus Disease 2019 [published online ahead of print, 2020 Jun 30]. *Clin Infect Dis*. 2020;ciaa851.

17. Wu J, Li W, Shi X, Chen Z, Jiang B, Liu J, Wang D, Liu C, Meng Y, Cui L, Yu J, Cao H, Li L. Early antiviral treatment contributes to alleviate the severity and improve the prognosis of patients with novel coronavirus disease (COVID-19). J Intern Med. 2020 Jul;288(1):128-138.

18. Weiss A, Jellingsø M, Sommer MOA. Spatial and temporal dynamics of SARS-CoV-2 in COVID-19 patients: A systematic review and meta-analysis. *EBioMedicine*. 2020;58:102916.

19. Doi Y, Hibino M, Hase R, et al. A Prospective, Randomized, Open-Label Trial of Early versus Late Favipiravir Therapy in Hospitalized Patients with COVID-19. *Antimicrob Agents Chemother*. 2020;64(12):e01897-20.

20. Goyal A, Lurie Y, Meissner EG, et al. Modeling HCV cure after an ultra-short duration of therapy with direct acting agents. *Antiviral Res*. 2017;144:281-285.

21. Saber-Ayad M, Saleh MA, Abu-Gharbieh E. The Rationale for Potential Pharmacotherapy of COVID-19. *Pharmaceuticals (Basel)*. 2020;13(5):96. Published 2020 May 14.

22. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. *JAMA*. 2020;323(13):1239-1242.

23. Uyeki, T. M., Bernstein, H. H., Bradley, J. S., Englund, J. A., File, T. M., Fry, A. M., et al.(2019). Clinical Practice Guidelines by the Infectious Diseases Society of America: 2018 Update on Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management of Seasonal Influenzaa. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 68(6), e1–e47.

24. Chan KS. Treatment of severe acute respiratory syndrome with lopinavir/ritonavir: a multicentre retrospective matched cohort study. Hong Kong Medical Journal 2003; 9: 399-406.

25. Kalil AC. Treating COVID-19–Off-Label Drug Use, Compassionate Use, and Randomized Clinical Trials During Pandemics. JAMA 2020.

26. Yu T, Tian C, Chu S, et al. COVID-19 patients benefit from early antiviral treatment: A comparative, retrospective study [published online ahead of print, 2020 Jun 3]. J Med Virol. 2020;10.1002

Figures

Ex patients

female	13	4
male	19	11

■ >65 years   ■ <=65 years

Figure 1

The relationship between age and survival by gender

Figure 2

The relationship between comorbidity type and survival HT: Hypertention, CAD: Coroner arter disease, PAH: Peripheral arter disease, HL: Hyperlipidemia, CHD: Congestive heart disease, DM: Diabetes mellitus, COPD: Chronic obstructive pulmoner disease

Favipiravir İnitiation Time

	ex	alive	total
≤3 day Favipiravir initiation	17	84	101
>3 day Favipiravir initiation	30	49	79

Figure 5

The relationship between Favipiravir initiation time and survival